Specifically, we wanted to determine if J54 (TLK1 inhibitor) or GLPG (MK5 inhibitor), as well as a genetic approach to knock down TLK1 and MK5 with shRNA, could alter the motility, invasion, and ultimately metastatic properties of PCa cell lines. The gene discussed is TLK1; the disease is posterior cortical atrophy.